About Cameron Gallagher
Cameron Gallagher chairs Crosslink, which develops biologic components intended to assemble cancer medicines inside solid tumors. He is president and CEO of Alessa Therapeutics, a clinical-stage company developing localized drug delivery for early prostate cancer. He has more than 33 years of biotechnology and pharmaceutical experience.
Earlier, he co-founded Zentalis Pharmaceuticals, a developer of small-molecule cancer medicines, and served as president and a board member. He was chief business officer at Retrosense Therapeutics, which developed gene therapies for inherited retinal disorders, through its acquisition by Allergan. That deal was worth up to $580 million. He now serves on four other boards, including Opus Genetics, SelectION and Immusoft. His past board roles include VelosBio, Retrosense and Zentalis. Merck acquired VelosBio for $2.8 billion. He earned a B.B.A. from Ohio University and an M.B.A. from the University of San Diego.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Cameron Gallagher in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Cameron Gallagher works with at each company, as listed on that company's latest Form D.
